Johnson & Johnson (JNJ) Stake Lowered by Stratos Wealth Partners LTD.
Stratos Wealth Partners LTD. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 110,892 shares of the company’s stock after selling 10,941 shares during the period. Johnson & Johnson comprises approximately 0.7% of Stratos Wealth Partners LTD.’s portfolio, making the stock its 26th biggest holding. Stratos Wealth Partners LTD.’s holdings in Johnson & Johnson were worth $14,417,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in JNJ. Harding Loevner LP bought a new position in Johnson & Johnson during the second quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. IHT Wealth Management LLC raised its holdings in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson during the second quarter valued at about $124,000. Finally, Shine Investment Advisory Services Inc. bought a new position in Johnson & Johnson during the second quarter valued at about $177,000. Institutional investors and hedge funds own 65.53% of the company’s stock.
Several research firms have weighed in on JNJ. Wells Fargo & Co restated an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a report on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Finally, Citigroup lifted their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $146.16.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The business had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same period last year, the business earned $1.58 earnings per share. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. analysts anticipate that Johnson & Johnson will post 8.08 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.